ClinicalTrials.gg
RecruitingNCT07950371Updated Nov 20, 2026

Effects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity

A Phase 4 interventional study of Tirzepatide and Placebo in Obesity (Disorder), sponsored by University Medical Centre Ljubljana. Recruiting at 2 sites in Slovenia. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by University Medical Centre Ljubljana · Phase 4, Interventional, and Basic science

How we know

Updated Nov 20, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 106 studies testing tirzepatide in Obesity — 62 open to participants now, 79 under way, 14 of them phase 3. Tirzepatide · Obesity.

Planned enrollment
85th of 106
30 · median 69
Started
2026
with 37 others
Phase 4
30 of 106
21 open now
Primary completion
2027-11
later than 42 of 78 live
Registered
106th of 106
by date
Lead sponsor
4 of 106
University Medical Centre Ljubljana

Among the 106 studies testing tirzepatide in Obesity, this one is the 85th largest by planned enrollment, is one of 38 that started in 2026, is one of 30 in phase 4, reaches primary completion later than 42 of the 78 other live ones, and was the 106th registered.

Obesity

11,564 studies on the registry are indexed under Obesity; 2,059 are open to participants now.

Browse Obesity studies →

Open to participants now

62 of the 106 studies testing tirzepatide in Obesity are open now, in 12 countries. Recruiting first, the newest first:

56 more — sign in →

By country, each count listing its studies:

All 62 open studies →

About tirzepatide

Tirzepatide: first FDA approval 2022 (MOUNJARO), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,350 Obesity studies recruiting now, 382 (28%) set no upper age limit and 864 (64%) stop at 75 or younger; 168 take children under 18; 490 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 106 studies testing tirzepatide in Obesity, or all of them as a file.
02

Study summary

This study investigates the effects of a dual glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist, tirzepatide, on corneal nerve morphology and other ocular parameters in adults with obesity. Participants, adult patients with obesity, will receive either tirzepatide or placebo over 24 weeks. Researchers will assess ophthalmological clinical status, corneal nerve changes, ocular surface, intraocular pressure, anterior-segment biometry and optical coherent tomography, and exophthalmometry. Orbital MRI will be performed in a subgroup of participants receiving tirzepatide. Optical coherence tomography and Optical coherence tomography angiography will be preformed to asses the posterior segment. The goal of this study is to investigate the effects of tirzepatide on corneal nerve morphology and functional consequences, as well as anterior segment parameters, during tirzepatide-induced weight loss, addressing an important gap in understanding the impact of incretin-based therapies on corneal nerves and anatomy of anterior eye segment.

03

Conditions studied

  • Obesity (Disorder)

Browse trials for

Keywords

  • Tirzepatide
  • Obesity
  • Corneal Nerve Fibres
  • Corneal Confocal Microscopy
  • Corneal Nerve Fibre Length
  • Corneal Nerve Regeneration
  • Corneal Sensitivity
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • between 30 kg/m² and 45 kg/m²
  • Stable body weight within the three months preceding study enrolment (defined as ≤ 5% change)
  • No previous pharmacological or surgical treatment of obesity
  • Appropriate and no planned pregnancy within 8 months following enrolment

Exclusion criteria

Exclusion Criteria:

  • Sarcopenic obesity
  • Pregnancy or lactation
  • status
  • Diabetes
  • Immobility
  • Personal history of
  • Personal history of pancreatitis
  • Personal history of major depressive episodes
  • Personal history of myopathy
  • Personal or family history of medullary thyroid carcinoma
  • Current treatment with metformin or systemic
  • Prior ocular trauma
  • Intraocular or corneal surgery
  • Laser refractive surgery
  • Corneal nerve-affecting disease such as neurotrophic keratitis
  • Active contact lens wear
  • Inability or unwillingness to comply with the protocol
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 4
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Tirzepatide Group

    Participants with obesity randomized to receive tirzepatide during the 24-week placebo-controlled study period. Ophthalmological assessments will be performed at baseline and Week 24 to evaluate treatment-related changes in ocular parameters.

    Drug: Tirzepatide

  • Placebo comparator
    Placebo Group

    Participants with obesity randomized to receive placebo during the initial 24-week study period. Ophthalmological assessments will be performed at baseline and Week 24 using the same protocol as in the tirzepatide group. Following the placebo-controlled period, participants will be offered tirzepatide treatment according to the study protocol.

    Drug: Placebo

Interventions

  • Tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, will be administered by subcutaneous injection once weekly. Treatment will begin at 2.5 mg weekly, with dose escalation in 2.5 mg increments every 4 weeks, according to tolerability, up to a maximum dose of 15 mg weekly.

  • DrugPlacebo

    Matching placebo (saline solution) will be administered by subcutaneous injection once weekly using injection pens identical in appearance to those containing tirzepatide. The administration schedule and injection procedures will mirror those of the active treatment to maintain blinding.

06

What researchers measure

Primary outcomes

  1. Change in Corneal Nerve Fibre

    Assessed by in vivo corneal confocal microscopy (Hedelberg Retina Tomograph -HRT3 Rostock Cornea Module, Heidelberg Engineering, Heidelberg Germany) and quantified with CCMetrics and SuperCCM softwares.

    Time frame: Baseline to Week 24

Secondary outcomes

  1. Corneal sensitivity

    Change in corneal sensitivity assessed using a semiquantitative cotton-wisp test. The corneal reflex will be evaluated by gently touching the corneal surface with a fine cotton fibre and classified into three categories: normal, diminished, or absent.

    Time frame: Baseline to Week 24

  2. Best-Corrected Visual Acuity Assessment

    Best-corrected visual acuity (BCVA) will be assessed using Snellen charts. Objective refraction will be measured using an autorefractometer, while subjective refraction will be performed using a phoropter or trial frames and lenses.

    Time frame: Baseline to Week 24

  3. Intraocular pressure

    Time frame: Baseline to Week 24

  4. Anterior segment parameters

    Assessed by Anterior segment optical coherent tomography Anterion (Heidelberg Engineering, Heidelberg Germany)

    Time frame: Baseline to Week 24

  5. Ocular surface

    Change in tear break-up time

    Time frame: Baseline to Week 24

  6. Exophthalmometry

    Change in Hertel measurement

    Time frame: Baseline to Week 24

  7. Orbital fat volume

    Change in MRI-derived orbital fat volume in participants from subgroup receiving Tirzepatide

    Time frame: Baseline to Week 24

  8. OCT and OCTA of the retina

    Posterior segment parameters will be assessed using optical coherence tomography (OCT) and optical coherence tomography angiography (OCTA) with the DRI OCT Triton system (Topcon, Inc., Tokyo, Japan).

    Time frame: Baseline to Week 24

  9. Change in Body Mass and composition

    Measured primarily as changes in body weight, waist circumference and body composition measured by dual-energy X-ray absorptiometry (DXA).

    Time frame: Baseline to Week 24

07

Study locations

2 of 2 sites recruiting
  • Department of Endocrinology, Diabetes and Metabolic Diseases, University Medical Centre Ljubljana
    Ljubljana, 1000, Slovenia
    Recruiting
    • Mojca Jensterle Sever, Prof., MD., Phd · Contactmojca.jensterlesever@kclj.si · +38631312977
    • Mojca Jensterle Sever, Prof, MD, PhD · Principal investigator
  • University Eye Hospital, University Medical Centre Ljubljana
    Ljubljana, 1000, Slovenia
    Recruiting
    • Špela Štunf Pukl, Prof., MD., Phd · Contactspela.stunf.pukl@kclj.si · +38641382487
    • Špela Štunf Pukl, Prof, MD, PhD · Principal investigator
    • David Petrovič, MD · Sub investigator
08

References and documents

Publications

  • Petrovic D, Mujnovic A, Hammami A, Krasovec T, Kirbis M, Stunf Pukl S. In Vivo Confocal Microscopy of the Cornea in Diagnosing Small Fibre Neuropathy: A Cross-Sectional Observational Study. Diagnostics (Basel). 2025 Aug 30;15(17):2207. doi: 10.3390/diagnostics15172207. PubMed 40941695 ↗
  • Toptan M, Elkan H, Erdogdu H, Goc O, Yilmaz OF. The Effects of Metabolic and Bariatric Surgery on the Anterior Segment Parameters of the Eye. Obes Surg. 2025 Apr;35(4):1234-1241. doi: 10.1007/s11695-025-07773-0. Epub 2025 Mar 14. PubMed 40085186 ↗
  • Gad H, Mohammed I, Dauleh H, Pasha M, Al-Barazenji T, Hussain K, Malik RA. Case report: Nerve fiber regeneration in children with melanocortin 4 receptor gene mutation related obesity treated with semaglutide. Front Endocrinol (Lausanne). 2024 Jun 21;15:1385463. doi: 10.3389/fendo.2024.1385463. eCollection 2024. PubMed 38974580 ↗
  • Azmi S, Ferdousi M, Liu Y, Adam S, Iqbal Z, Dhage S, Ponirakis G, Siahmansur T, Marshall A, Petropoulos I, Kalteniece A, Ho JH, Syed A, Gibson JM, Ammori BJ, Durrington PN, Malik RA, Soran H. Bariatric surgery leads to an improvement in small nerve fibre damage in subjects with obesity. Int J Obes (Lond). 2021 Mar;45(3):631-638. doi: 10.1038/s41366-020-00727-9. Epub 2021 Jan 27. PubMed 33504933 ↗
  • Gad H, Petropoulos IN, Khan A, Ponirakis G, MacDonald R, Alam U, Malik RA. Corneal confocal microscopy for the diagnosis of diabetic peripheral neuropathy: A systematic review and meta-analysis. J Diabetes Investig. 2022 Jan;13(1):134-147. doi: 10.1111/jdi.13643. Epub 2021 Aug 27. PubMed 34351711 ↗

Individual participant data

Plan to share: Yes — De-identified individual participant data (IPD) to be shared will include demographic data, anthropometric measurements, body composition assessments (body weight, waist circumference, and DXA-derived parameters), and ophthalmological assessment data, including corneal nerve fibre parameters obtained by in vivo corneal confocal microscopy, corneal sensitivity, best-corrected visual acuity, intraocular pressure, anterior segment OCT parameters, tear break-up time, Hertel exophthalmometry measurements, and posterior segment OCT and OCTA parameters. MRI-derived orbital fat volume measurements will be included for participants in the MRI subgroup. All shared data will be fully de-identified, and no directly identifiable personal information will be included.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Nov 2027, 11 months later.

Of 190 non-industry phase 4 interventional studies under Obesity, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 52. This study's planned 11 months is below that.

Counting every sponsor, half of 210 studies reached it within 31 months; a quarter within 15 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 15, 2026
First posted
Nov 20, 2026
StartEst.
Dec 1, 2026
Primary completionEst.
Nov 1, 2027
CompletionEst.
Dec 1, 2027
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07950371
Responsible party
Špela Štunf Pukl (Špela Štunf Pukl, Prof.MD, PhD, University Eye Hospital, University Medical Centre Ljubljana, University Medical Centre Ljubljana) — Principal investigator
First posted
Nov 20, 2026
Start date
Dec 1, 2026 (estimated)
Primary completion
Nov 1, 2027 (estimated)
Completion
Dec 1, 2027 (estimated)
Last update
Nov 20, 2026

Study contacts

Špela Štunf Pukl, Prof, MD, PhD
Contact
spela.stunf.pukl@kclj.si
+38641382487
David Petrovič, MD
Contact
david.petrovic@kclj.si
+38670843048
Špela Štunf Pukl, Prof, MD, PhD
principal investigator · University Eye Hospital, University Medical Centre Ljubljana

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tirzepatide

Start the discussion